These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 20451663)

  • 21. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.
    Kane SV; Jaganathan S; Bedenbaugh AV; Palmer L; Schwartz DA
    Curr Med Res Opin; 2014 Sep; 30(9):1821-6. PubMed ID: 24884302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.
    Schreiber S; Rutgeerts P; Fedorak RN; Khaliq-Kareemi M; Kamm MA; Boivin M; Bernstein CN; Staun M; Thomsen OØ; Innes A;
    Gastroenterology; 2005 Sep; 129(3):807-18. PubMed ID: 16143120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Certolizumab pegol: in Crohn's disease.
    Blick SK; Curran MP
    BioDrugs; 2007; 21(3):195-201; discussion 202-3. PubMed ID: 17516714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey.
    Vavricka SR; Schoepfer AM; Bansky G; Binek J; Felley C; Geyer M; Manz M; Rogler G; de Saussure P; Sauter B; Scharl M; Seibold F; Straumann A; Michetti P;
    Inflamm Bowel Dis; 2011 Jul; 17(7):1530-9. PubMed ID: 21674709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease.
    Shao LM; Chen MY; Cai JT
    Aliment Pharmacol Ther; 2009 Mar; 29(6):605-14. PubMed ID: 19183161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful treatment of fistulizing Crohn's disease with certolizumab pegol.
    Danese S; Stefanelli T; Omodei P; Zatelli S; Bonifacio C; Balzarini L; Repici A; Malesci A
    Inflamm Bowel Dis; 2008 Feb; 14(2):292-3. PubMed ID: 17932987
    [No Abstract]   [Full Text] [Related]  

  • 27. Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease.
    Stein AC; Rubin DT; Hanauer SB; Cohen RD
    Inflamm Bowel Dis; 2014 Oct; 20(10):1722-8. PubMed ID: 25171509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Crohn's disease--infliximab, adalimumab and certolizumab-pegol: clinical value of anti-TNF-alpha treatment].
    Schreiber S
    Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1770-4. PubMed ID: 17713889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use.
    Danese S; Mocciaro F; Guidi L; Scribano ML; Comberlato M; Annese V; Colombo E; Stefanelli T; Marzo M; Vangeli M; Pulitano' R; Manca A; Armuzzi A; Malesci A; Prantera C; Cottone M
    Inflamm Bowel Dis; 2008 Aug; 14(8):1168-70. PubMed ID: 18357580
    [No Abstract]   [Full Text] [Related]  

  • 30. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study.
    Lee SD; Rubin DT; Sandborn WJ; Randall C; Younes Z; Schreiber S; Schwartz DA; Burakoff R; Binion D; Dassopoulos T; Arsenescu R; Gutierrez A; Scherl E; Kayhan C; Hasan I; Kosutic G; Spearman M; Sen D; Coarse J; Hanauer S
    Inflamm Bowel Dis; 2016 Aug; 22(8):1870-80. PubMed ID: 27400222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.
    Colombel JF; Sandborn WJ; Allez M; Dupas JL; Dewit O; D'Haens G; Bouhnik Y; Parker G; Pierre-Louis B; Hébuterne X
    Clin Gastroenterol Hepatol; 2014 Mar; 12(3):423-31.e1. PubMed ID: 24184736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Certolizumab pegol for induction of remission in Crohn's disease.
    Yamazaki H; So R; Matsuoka K; Kobayashi T; Shinzaki S; Matsuura M; Okabayashi S; Kataoka Y; Tsujimoto Y; Furukawa TA; Watanabe N
    Cochrane Database Syst Rev; 2019 Aug; 8(8):CD012893. PubMed ID: 31476018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease.
    Tun GS; Lobo AJ
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):317-27. PubMed ID: 25586216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.
    Fleischmann R; Vencovsky J; van Vollenhoven RF; Borenstein D; Box J; Coteur G; Goel N; Brezinschek HP; Innes A; Strand V
    Ann Rheum Dis; 2009 Jun; 68(6):805-11. PubMed ID: 19015206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease.
    Stidham RW; Lee TC; Higgins PD; Deshpande AR; Sussman DA; Singal AG; Elmunzer BJ; Saini SD; Vijan S; Waljee AK
    Aliment Pharmacol Ther; 2014 Jun; 39(12):1349-62. PubMed ID: 24749763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
    Gisbert JP; Marín AC; McNicholl AG; Chaparro M
    Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of certolizumab pegol for Crohn's disease: a systematic review and meta-analysis.
    Da W; Zhu J; Wang L; Lu Y
    Adv Ther; 2013 May; 30(5):541-53. PubMed ID: 23681504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial.
    Sandborn WJ; Schreiber S; Feagan BG; Rutgeerts P; Younes ZH; Bloomfield R; Coteur G; Guzman JP; D'Haens GR
    Clin Gastroenterol Hepatol; 2011 Aug; 9(8):670-678.e3. PubMed ID: 21642014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: a systematic review and network meta-analysis.
    Singh S; Garg SK; Pardi DS; Wang Z; Murad MH; Loftus EV
    Mayo Clin Proc; 2014 Dec; 89(12):1621-35. PubMed ID: 25441399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Certolizumab pegol: a polyethylene glycolated Fab' fragment of humanized anti-tumor necrosis factor alpha monoclonal antibody for the treatment of Crohn's disease.
    Baker DE
    Rev Gastroenterol Disord; 2008; 8(4):240-53. PubMed ID: 19107098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.